Evidence Snapshot

Myosin light chain kinase, smooth muscle

CHEMBL2428 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:41:04Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:41 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2428

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Myosin light chain kinase, smooth muscle as ChEMBL target CHEMBL2428, mapped to UniProt Q15746. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Myosin light chain kinase, smooth muscle

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2428

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q15746

Myosin light chain kinase, smooth muscle

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Myosin light chain kinase, smooth muscle matters

As of 2026-09-13

Myosin light chain kinase, smooth muscle is reviewed as Myosin light chain kinase, smooth muscle (UniProt Q15746); the current evidence base includes 13 approved drugs, 924 compounds, and 302 assays, with lead potency reaching pChEMBL 9.5.

Protein context

Myosin light chain kinase, smooth muscle

Myosin light chain kinase, smooth muscle Sequence length is 1914 aa.

Review this target as Myosin light chain kinase, smooth muscle, mapped to UniProt Q15746. Sequence length is 1914 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q15746 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 924 compounds, and 302 assays for this target. The dominant activity type is KD. CHEMBL5653589 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL5653589 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine

13 approved pChEMBL 9.5

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Myosin light chain kinase, smooth muscle matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q15746, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

924

Total Compounds

302

Total Assays

Approved Drugs

IC50: 134.0, KI: 30.0, EC50: 1.0, KD: 391.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5653589	9.5	Kd	—
No preferred name CHEMBL1090090	8.5	Kd	Clinical
No preferred name CHEMBL388978	8.0	IC50	—
No preferred name CHEMBL464552	8.0	Kd	—
No preferred name CHEMBL603469	7.9	Kd	Clinical

Approved Drugs

Structure	Compound	First Approval
	QUIZARTINIB CHEMBL576982	2023
	FEDRATINIB CHEMBL1287853	2019
	GILTERITINIB CHEMBL3301622	2018
	MIDOSTAURIN CHEMBL608533	2017
	NINTEDANIB CHEMBL502835	2014
	PONATINIB CHEMBL1171837	2012
	BOSUTINIB CHEMBL288441	2012
	RUXOLITINIB CHEMBL1789941	2011
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:41:04Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:41 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2428